Exercise program adherence using a 5-kilometer (5k) event as an achievable goal in people with schizophrenia

Biological Research for Nursing

Volumn 13, Issue 4, 2011, Pages 383-390

  Warren, Kimberly R ^a   Ball, M Patricia ^a   Feldman, Stephanie ^a   Liu, Fang ^a   McMahon, Robert P ^a   Kelly, Deanna L ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

5K; healthy behavior; schizophrenia; weight gain; weight management

Indexed keywords

ADULT; ARTICLE; EXERCISE; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; SCHIZOPHRENIA;

ADULT; EXERCISE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SCHIZOPHRENIA;

EID: 80455129028     PISSN: 10998004     EISSN: 15524175     Source Type: Journal    
DOI: 10.1177/1099800410393272     Document Type: Article

References (58)

1. Allison D. B.,Newcomer J. W.,Dunn A. L.,Blumenthal J. A.,Fabricatore A. N.,Daumit G. L.,Alpert J. E.Obesity among those with mental disorders: A National Institute of Mental Health meeting report.American Journal of Preventive Medicine. 2009;36:341-350.
2. Consensus development conference on antipsychotic drugs and obesity and diabetes.Diabetes Care. 2004;27:596-601.
3. American Heart Association. (2010). Metabolic syndrome. Retrieved March 1, 2010, from http://www.americanheart.org/presenter.jhtml?identifier=4756.
4. Andreasen N. C.Negative symptoms in schizophrenia. Definition and reliability.Archives of General Psychiatry. 1982;39:784-788.
5. Archie S.,Wilson J. H.,Osborne S.,Hobbs H.,McNiven J.Pilot study: Access to fitness facility and exercise levels in olanzapine-treated patients.Canadian Journal of Psychiatry. 2003;48:628-632.
6. Arndt S.,Davis C. S.,Miller D. D.,Andreasen N. C.Effect of antipsychotic withdrawal on extrapyramidal symptoms: Statistical methods for analyzing single-sample repeated-measures data.Neuropsychopharmacology. 1993;8:67-75.
7. Ball M. P.,Coons V. B.,Buchanan R. W.A program for treating olanzapine-related weight gain.Psychiatric Services. 2001;52:967-969.
8. Beebe L. H.Walking tall: A person with schizophrenia on a journey to better health.Journal of Psychosocial Nursing and Mental Health Services. 2006;44:53-55.
9. Beebe L. H.,Burk R.,McIntyre K. B.,Smith K.,Velligan D. I.,Resnick B.,Dessieux O.Motivating persons with schizophrenia spectrum disorders to exercise: Rationale and design.Clinical Schizophrenia and Related Psychoses. 2009;3:111-116.
10. Beebe L. H.,Tian L.,Morris N.,Goodwin A.,Allen S. S.,Kuldau J.Effects of exercise on mental and physical health parameters of persons with schizophrenia.Issues in Mental Health Nursing. 2005;26:661-676.
11. Bleuler E.Dementia praecox or the group of schizophrenias. New York, NY: International Universities Press; 1950:.
12. Brar J. S.,Ganguli R.,Pandina G.,Turkoz I.,Berry S.,Mahmoud R.Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.Journal of Clinical Psychiatry. 2005;66:205-212.
13. Bushe C.,Haddad P.,Peveler R.,Pendlebury J.The role of lifestyle interventions and weight management in schizophrenia.Journal of Psychopharmacology. 2005;19:28-35.
14. Bushe C. J.,McNamara D.,Haley C.,McCrossan M. F.,Devitt P.Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation.BMC Psychiatry. 2008;8:76.
15. Centorrino F.,Wurtman J. J.,Duca K. A.,Fellman V. H.,Fogarty K. V.,Berry J. M.,Baldessarini R. J.Weight loss in overweight patients maintained on atypical antipsychotic agents.International Journal of Obesity (Lond). 2006;30:1011-1016.
16. Chen C. K.,Chen Y. C.,Huang Y. S.Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: A 12-month follow up.Psychiatry and Clinical Neurosciences. 2009;63:17-22.
17. Daumit G. L.,Goff D. C.,Meyer J. M.,Davis V. G.,Nasrallah H. A.,McEvoy J. P.,Lieberman J. A.Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.Schizophrenia Research. 2008;105:175-187.
18. De Hert M.,Correll C. U.,Cohen D.Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.Schizophrenia Research. 2010;18:18-24.
19. DeRenzo E. G.,Conley R. R.,Love R.Assessment of capacity to give consent to research participation: State-of-the-art and beyond.Journal of Health Care Law Policy. 1998;1:66-87.
20. Dishman R.Increasing and maintaining exercise and physical activity.Behavioral Therapy. 1991;21:345-373.
21. First M. B.,Spitzer R. L.,Gibbon M.,Williams J. B. W.Structured clinical interview for DSM-IV axis I disorders (SCID-I/P). New York, NY: Psychiatric Institute, Biometrics Research Department; 1997:.
22. Floel A.,Ruscheweyh R.,Kruger K.,Willemer C.,Winter B.,Volker K.,Knecht S.Physical activity and memory functions: Are neurotrophins and cerebral gray matter volume the missing link?.Neuroimage. 2010;49:2756-2763.
23. Fogarty M.,Happell B.,Pinikahana J.The benefits of an exercise program for people with schizophrenia: A pilot study.Psychiatric Rehabilitation Journal. 2004;28:173-176.
24. Gaitero Calleja A. M.,Santed German M. A.,Rullas Trincado M.,Grande de Lucas A.Cognitive behavioral weight-loss program for individuals with psychotic mental diseases.Psicothema. 2007;19:640-645.
25. Gimino F. A.,Levin S. J.The effects of aerobic exercise on perceived self-image in post-hospitalized schizophrenic patients.Medicine and Science in Sports and Exercise. 1984;16:139.
26. Gondoh Y.,Sensui H.,Kinomura S.,Fukuda H.,Fujimoto T.,Masud M.,Takekura H.Effects of aerobic exercise training on brain structure and psychological well-being in young adults.Journal of Sports Medicine and Physical Fitness. 2009;49:129-135.
27. Guy W.ECDEU assessment manual for psychopharmacology. Guy W., ed. Rockville, MD: National Institute for Mental Health; 1976:218 76-222 338.
28. Hainer V.,Toplak H.,Stich V.Fat or fit: What is more important?.Diabetes Care. 2009;32:S392-S397.
29. Haro J. M.,Novick D.,Suarez D.,Roca M.Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.Journal of Psychiatric Research. 2009;43:265-273.
30. Heinrichs D. W.,Hanlon T. E.,Carpenter W. T.,.The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome.Schizophrenia Bulletin. 1984;10:388-398.
31. Honea R. A.,Thomas G. P.,Harsha A.,Anderson H. S.,Donnelly J. E.,Brooks W. M.,Burns J.M.Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer disease.Alzheimer Disease and Associated Disorders. 2009;23:188-197.
32. Jean-Baptiste M.,Tek C.,Liskov E.,Chakunta U. R.,Nicholls S.,Hassan A. Q.,Wexler B. E.A pilot study of a weight management program with food provision in schizophrenia.Schizophrenia Research. 2007;96:198-205.
33. Kelly D. L.,McMahon R. P.,Liu F.,Love R. C.,Wehring H. J.,Shim J. C.,Conley R. R.Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: A retrospective cohort study.Journal of Clinical Psychiatry. 2010;71:304-311.
34. Kraepelin E.Dementia praecox and paraphrenia. Edinburgh, UK: Livingstone; 1919:.
35. Kwon J. S.,Choi J. S.,Bahk W. M.,Yoon Kim C.,Hyung Kim C.,Chul Shin Y.,Geun Oh C.Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.Journal of Clinical Psychiatry. 2006;67:547-553.
36. Lee C. D.,Sui X.,Blair S. N.Combined effects of cardiorespiratory fitness, not smoking, and normal waist girth on morbidity and mortality in men.Archives of Internal Medicine. 2009;169:2096-2101.
37. Lee S. J.,Choi E. J.,Kwon J. S.A naturalistic multicenter trial of a 12-week weight management program for overweight and obese patients with schizophrenia or schizoaffective disorder.Journal of Clinical Psychiatry. 2008;69:555-562.
38. Maayan L. A.,Vakhrusheva J.Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment.Human Psychopharmacology. 2010;25:133-138.
39. Mandic S.,Myers J.,Oliveira R. B.,Abella J.,Froelicher V. F.Characterizing differences in mortality at the low end of the fitness spectrum in individuals with cardiovascular disease.European Journal of Cardiovascular Prevention and Rehabilitation. 2009;17:289-295.
40. McCreadie R. G.Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study.British Journal of Psychiatry. 2003;183:534-539.
41. Menza M.,Vreeland B.,Minsky S.,Gara M.,Radler D. R.,Sakowitz M.Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program.Journal of Clinical Psychiatry. 2004;65:471-477.
42. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA. 2001;285:2486-2497.
43. Newcomer J. W.Antipsychotic medications: Metabolic and cardiovascular risk.Journal of Clinical Psychiatry. 2007a;68:8-13.
44. Newcomer J. W.Metabolic syndrome and mental illness.American Journal of Managed Care. 2007b;13:170-177.
45. Newcomer J. W.Introduction: Cardiovascular disease and metabolic risk factors in patients with mental illness.CNS Spectrums. 2008;13:1-14.
46. Novick D.,Haro J. M.,Perrin E.,Suarez D.,Texeira J. M.Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.European Neuropsychopharmacology. 2009;19:542-550.
47. Overall J. E.,Gorham D. R.The Brief Psychiatric Rating Scale.Psychological Reports. 1962;10:812.
48. Pajonk F. G.,Wobrock T.,Gruber O.,Scherk H.,Berner D.,Kaizl I.,Falkai P.Hippocampal plasticity in response to exercise in schizophrenia.Archives of General Psychiatry. 2010;67:133-143.
49. Pelham T. W.,Campagna P. D.,Ritvo P. G.,Birnie W. A.The effects of exercise therapy on clients in a psychiatric rehabilitation program.Psychosocial Rehabilitation Journal. 1993;16:75-84.
50. Pendlebury J.,Bushe C. J.,Wildgust H. J.,Holt R. I.Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK.Acta Psychiatrica Scandinavica. 2007;115:286-294.
51. Pendlebury J.,Haddad P.,Dursun S.Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results.Human Psychopharmacology. 2005;20:447-448.
52. Smith S.,Yeomans D.,Bushe C. J.,Eriksson C.,Harrison T.,Holmes R.,Sullivan G.A well-being programme in severe mental illness. Baseline findings in a UK cohort.International Journal of Clinical Practice. 2007;61:1971-1978.
53. Spelman L. M.,Walsh P. I.,Sharifi N.,Collins P.,Thakore J. H.Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia.Diabetic Medicine. 2007;24:481-485.
54. Strassnig M.,Brar J. S.,Ganguli R.Body mass index and quality of life in community-dwelling patients with schizophrenia.Schizophrenia Research. 2003;62:73-76.
55. Tiihonen J.,Lonnqvist J.,Wahlbeck K.,Klaukka T.,Niskanen L.,Tanskanen A.,Haukka J.11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study).Lancet. 2009;374:620-627.
56. U.S. Department of Health and Human Services. (2008). 2008 Physical Activity Guidelines for Americans. 2010. Retrieved fromhttp://www.health.gov/paguidelines.
57. Vreeland B.,Minsky S.,Menza M.,Rigassio Radler D.,Roemheld-Hamm B.,Stern R.A program for managing weight gain associated with atypical antipsychotics.Psychiatric Services. 2003;54:1155-1157.
58. Weber M.,Wyne K.A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics.Schizophrenia Research. 2006;83:95-101.